Merck Return on Investment 2010-2022 | MRK

Current and historical return on investment (ROI) values for Merck (MRK) over the last 10 years.
Merck ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-09-30 $18.55B $73.01B 25.98%
2022-06-30 $19.36B $72.00B 28.55%
2022-03-31 $15.99B $71.54B 24.92%
2021-12-31 $13.20B $68.95B 22.35%
2021-09-30 $6.07B $58.77B 11.14%
2021-06-30 $3.66B $57.42B 6.81%
2021-03-31 $4.40B $51.04B 8.32%
2020-12-31 $5.55B $50.76B 10.66%
2020-09-30 $7.37B $55.59B 14.30%
2020-06-30 $7.48B $53.90B 14.94%
2020-03-31 $8.50B $47.94B 17.28%
2019-12-31 $7.93B $48.74B 15.91%
2019-09-30 $12.33B $49.60B 25.02%
2019-06-30 $12.38B $50.51B 24.74%
2019-03-31 $11.19B $50.39B 22.12%
2018-12-31 $8.93B $46.69B 17.22%
2018-09-30 $8.12B $52.59B 14.98%
2018-06-30 $5.60B $52.73B 9.98%
2018-03-31 $5.86B $55.40B 10.06%
2017-12-31 $6.80B $55.92B 11.27%
2017-09-30 $3.77B $60.34B 6.04%
2017-06-30 $6.69B $61.42B 10.41%
2017-03-31 $5.82B $63.53B 8.86%
2016-12-31 $5.50B $64.58B 8.24%
2016-09-30 $8.44B $67.61B 12.47%
2016-06-30 $7.71B $67.09B 11.30%
2016-03-31 $7.79B $67.56B 11.27%
2015-12-31 $7.55B $68.60B 10.68%
2015-09-30 $7.12B $69.80B 10.12%
2015-06-30 $6.48B $70.71B 9.41%
2015-03-31 $6.15B $73.42B 9.04%
2014-12-31 $6.68B $67.49B 9.88%
2014-09-30 $7.05B $63.93B 10.22%
2014-06-30 $7.82B $67.11B 10.98%
2014-03-31 $7.90B $72.15B 10.89%
2013-12-31 $7.67B $72.87B 10.58%
2013-09-30 $7.73B $72.65B 10.71%
2013-06-30 $7.64B $72.63B 10.47%
2013-03-31 $8.94B $71.70B 12.25%
2012-12-31 $9.88B $71.72B 13.49%
2012-09-30 $9.91B $75.78B 13.50%
2012-06-30 $9.91B $72.73B 13.63%
2012-03-31 $9.54B $72.54B 13.06%
2011-12-31 $8.98B $72.47B 12.30%
2011-09-30 $6.54B $73.29B 8.97%
2011-06-30 $5.58B $73.71B 7.69%
2011-03-31 $4.62B $72.48B 6.41%
2010-12-31 $3.36B $72.29B 4.60%
2010-09-30 $3.56B $72.08B 4.80%
2010-06-30 $3.78B $71.50B 5.86%
2010-03-31 $3.76B $75.62B 6.91%
2009-12-31 $4.02B $77.58B 9.57%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $278.995B $48.704B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $467.679B 18.00
Eli Lilly (LLY) United States $356.089B 44.94
AbbVie (ABBV) United States $289.429B 12.00
Novo Nordisk (NVO) Denmark $287.171B 37.66
Pfizer (PFE) United States $285.774B 7.81
Novartis AG (NVS) Switzerland $199.112B 15.00